AlphAIAlphAI — Financial news for AI agents
Stock TitanMAY 122 min read$TYRA

[144] Tyra Biosciences, Inc. SEC Filing

This article reports on a Form 144 SEC filing by Tyra Biosciences, Inc. (TYRA) related to a proposed sale of securities. The filing details include information about the filer, the issuer, the class of securities being sold (Common stock), the aggregate market value, and previous sales by Daniel Bensen. The filing also mentions the relationship of the seller to the issuer and provides a detailed breakdown of the acquisition of the securities.

Original reporting
Stock Titan
Published May 12, 2026, 9:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 12, 2026, 10:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$TYRA
Neutral
medium confidence
Mentioned
$TYRA
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$TYRANeutralLow
01

Why it matters

The filing may lead to short-term stock price adjustments; long-term effects depend on how the capital is utilized and market reception.

02

Market read

The event is specific to Tyra Biosciences; limited immediate impact on broader markets but relevant for investors and traders in the biotech sector.

03

What to watch

Details on the sale size, purpose, and market conditions are missing; these could significantly alter the impact assessment.

Timing: short-term

Background

Tyra Biosciences, Inc. filed SEC Form 144 indicating a proposed sale of common stock, suggesting strategic capital raising.

Company-level read

Ticker impact

$TYRANeutralMedium confidence
Context

The SEC filing pertains to a proposed sale of securities by Tyra Biosciences, Inc., which may influence investor perception and stock liquidity.

Expected impact

Potential short-term decrease in stock price due to increased supply; long-term impact depends on use of raised funds.

Evidence & confidence

The filing suggests a possible dilution event; however, without details on the sale size relative to market cap or strategic context, the impact remains uncertain.

Market effects

Sector

Limited sector impact; biotech sector may experience slight volatility if multiple filings occur.

Regional

Minimal regional effects; company-specific event.

Global

Negligible; specific to Tyra Biosciences and its investors.

Counterpoint

What could challenge this read

The securities sale might be a positive signal, indicating Tyra Biosciences is raising capital for growth initiatives, potentially leading to future stock appreciation.

Key entities

  • Company
    Tyra Biosciences, Inc.

    Biotech company focused on developing targeted therapies.

  • Insider/Related Party
    Daniel Bensen

    Seller of securities as per the SEC filing.

Read at source← All news

Related articles

SEP 9
$TYRAHighAI 8/10

Why Is Tyra Biosciences Stock Sinking Wednesday? - Tyra Biosciences (NASDAQ:TYRA)

Tyra Biosciences (NASDAQ:TYRA) shares fell 21.6% after Phase 2 trial results for dabogratinib showed an 86% overall response rate in patients with target exposure, but a 57% complete response rate at 60 mg, below analyst expectations of 70-80%. The company plans to advance to Phase 3 development and expand the study to a 70 mg cohort. Initial upper tract urothelial cancer study results were positive.

benzinga.com2 min
SEP 9
$TYRAHighAI 8/10

Why is Tyra Biosciences stock plunging today?

Tyra Biosciences (TYRA) stock fell 31.1% to $18.42 after Phase 2 trial results for dabogratinib showed a 64% complete response rate, below the 70% analyst consensus. Piper Sandler and H.C. Wainwright had modeled a 70% rate as the success threshold. The stock had risen 13% the prior week. Broader market caution added to the decline.

investing.com2 min
SEP 9
$TYRAHighAI 9/10

Tyra Biosciences stock tumbles 30% on phase 2 trial results

Tyra Biosciences (NASDAQ: TYRA) shares dropped 30% after reporting Phase 2 trial results for dabogratinib. The drug showed a 79% overall response rate and 64% complete response rate in combined patients. The trial enrolled 44 participants, with safety results indicating low rates of severe adverse events. Tyra plans to continue enrollment and engage with health authorities for Phase 3 study design.

investing.com2 min
SEP 8
$TYRAMed

Piper Sandler reiterates Tyra Biosciences stock rating ahead of data

Piper Sandler reiterated an Overweight rating and $56 price target for Tyra Biosciences (NASDAQ: TYRA) ahead of clinical trial data. The stock has risen 13% in a week and 136% in a year, trading at $28.60. Piper Sandler expects a 70% response rate for dabogratinib in bladder cancer trials, which could advance the drug to Phase 3. The firm sees a $1B+ opportunity in this market. Other analysts also maintain Buy ratings with targets up to $45.

investing.com2 min